567 related articles for article (PubMed ID: 6458884)
1. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
Møller NE; Høiby N
Scand J Infect Dis Suppl; 1981; 29():87-91. PubMed ID: 6458884
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. A study of carbenicillin, azlocillin or piperacillin in combination with tobramycin.
Møller NE; Eriksen KR; Feddersen C; Flensborg EW; Høiby N; Norn S; Rosendal K; Schiøtz PO; Skov PS
Eur J Respir Dis; 1982 Mar; 63(2):130-9. PubMed ID: 6461561
[TBL] [Abstract][Full Text] [Related]
3. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
Ciofu O; Giwercman B; Pedersen SS; Høiby N
APMIS; 1994 Sep; 102(9):674-80. PubMed ID: 7946270
[TBL] [Abstract][Full Text] [Related]
4. Tobramycin and carbenicillin compared with gentamicin and carbenicillin in the treatment of infection with Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Hodson ME; Wingfield HJ; Batten JC
Br J Dis Chest; 1983 Jan; 77(1):71-7. PubMed ID: 6407508
[TBL] [Abstract][Full Text] [Related]
5. Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations.
Wu YL; Scott EM; Po AL; Tariq VN
APMIS; 1999 Jun; 107(6):585-92. PubMed ID: 10379686
[TBL] [Abstract][Full Text] [Related]
6. Azlocillin in cystic fibrosis.
Malmborg AS; Alfredsson H; Strandvik B
Isr J Med Sci; 1983 Nov; 19(11):1001-3. PubMed ID: 6662681
[TBL] [Abstract][Full Text] [Related]
7. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
Ratjen F; Munck A; Kho P; Angyalosi G;
Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339
[TBL] [Abstract][Full Text] [Related]
8. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
Ratjen F; Brockhaus F; Angyalosi G
J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L
Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of azlocillin, carbenicillin, mezlocillin and piperacillin against Pseudomonas aeruginosa.
Høiby N; Bremmelgaard A; Schouenborg P
Scand J Infect Dis Suppl; 1981; 29():27-30. PubMed ID: 6458882
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin.
Heilesen AM; Permin H; Koch C; Høiby N
Scand J Infect Dis; 1983; 15(3):271-6. PubMed ID: 6417770
[TBL] [Abstract][Full Text] [Related]
12. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
13. Azlocillin with and without an aminoglycoside against respiratory tract infections in children with cystic fibrosis.
Michalsen H; Bergan T
Scand J Infect Dis Suppl; 1981; 29():92-7. PubMed ID: 6947408
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy of chronic infections with mucoid Pseudomonas aeruginosa in lower airways of patients with cystic fibrosis.
Friis B
Scand J Infect Dis; 1979; 11(3):211-7. PubMed ID: 118525
[TBL] [Abstract][Full Text] [Related]
15. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
Griese M; Müller I; Reinhardt D
Eur J Med Res; 2002 Feb; 7(2):79-80. PubMed ID: 11891148
[TBL] [Abstract][Full Text] [Related]
16. [Pseudomonas infections in lungs of children born with cystic fibrosis. Effects and adverse effects during antibiotic therapy with tobramycin and carbenicillin].
Friis B; Thomsen J
Ugeskr Laeger; 1979 Jul; 141(29):1968-72. PubMed ID: 545764
[No Abstract] [Full Text] [Related]
17. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
[TBL] [Abstract][Full Text] [Related]
18. Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases.
Holby N; Olling S
Acta Pathol Microbiol Scand C; 1977 Apr; 85(2):107-14. PubMed ID: 404841
[TBL] [Abstract][Full Text] [Related]
19. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection.
Johansen HK; Nørregaard L; Gøtzsche PC; Pressler T; Koch C; Høiby N
Pediatr Pulmonol; 2004 May; 37(5):427-32. PubMed ID: 15095326
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
